Affluent Medical signs agreements for mitral valve technologies with EUR 15M
upfront payment

EQS-News: Affluent Medical SA / Key word(s): Agreement
Affluent Medical signs agreements for mitral valve technologies with EUR 15M
upfront payment

12.07.2024 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Affluent Medical signs agreements for mitral valve technologies with EUR 15M
upfront payment

Aix-en-Provence, July 12, 2024 - 7:45 am - Affluent Medical (ISIN:
FR0013333077 - Ticker: AFME - "Affluent"), a French clinical-stage medical
technology company specializing in the international development and
industrialization of innovative medical devices, today announced that it has
signed several agreements with Edwards Lifesciences ("Edwards") related to
Affluent's structural heart products (adjustable mitral annulus Kalios(TM)) and
technologies (mitral valve technology). Under the terms of these agreements,
Affluent will receive EUR 15 million upfront as a cash payment. The
agreements are as follows:

  * An upfront payment of EUR 5 million for an exclusive option to acquire
    Kephalios, Affluent's wholly owned subsidiary supporting the Kalios(TM)
    innovative adjustable mitral ring, based on clinical outcomes from its
    study. The operational activities for the development of Kalios(TM) will
    continue to be managed exclusively by Affluent during the life of the
    option.

  * An upfront payment of EUR 5 million for the global, non-exclusive
    license of Affluent's intellectual property for the biomimetic cardiac
    mitral valve replacement technology, restricted to open-heart surgery.
    Affluent is eligible to receive additional future royalties on all
    potentially commercialized products using the licensed patents for the
    lifetime of these patents. Affluent retains full patent rights for
    transcatheter valves, including its Epygon mitral valve currently in
    clinical development.

  * An upfront payment of EUR 5 million for an equity stake in Affluent. The
    subscription agreement will be carried out via a capital increase with
    cancellation of shareholders' preferential subscription rights through
    an offer reserved for categories of beneficiaries (the "Capital
    Increase"). The subscription price of EUR1.38 (including EUR0.10 nominal
    value and EUR1.28 share premium) per new share represents a 15% discount
    to the volume-weighted average price of the Company's shares over the
    last 20 trading days preceding July 11, 2024. Upon successful closing of
    the transaction, Edwards will become a 9.21% shareholder in Affluent.
    FPCI Truffle Medeor and Ginko Invest will also participate in the
    Capital Increase by setting off their shareholder loans, granted to
    Affluent in April 2024 (see press release dated 25 April 2024). As a
    result of the Capital Increase, 6,190,831 new ordinary shares of the
    Company will be issued, for a total cumulative amount, including issue
    premium, of EUR8,543,346.78. Following the transaction, the share capital
    of Affluent Medical will be composed of 39,336,524 shares. Based on the
    Company's share capital at the date of the Prospectus and on an
    undiluted basis, a shareholder owning 1% of the share capital before the
    transaction would be diluted to 0.84% of the share capital after
    completion of the Capital Increase. The Capital Increase will be subject
    to the filing and approval of a prospectus by the Autorité des marchés
    financiers for technical reasons pursuant to Article 1, paragraph 5a, of
    Regulation (EU) No. 2017/1129. A separate press release announcing the
    approval of the prospectus will be issued by Affluent.

Sébastien Ladet, CEO of Affluent Medical, said "We are proud to sign these
agreements with the global leader in structural heart innovation. We look
forward to welcoming Edwards as a shareholder in our company. Edwards'
strong global market presence and commercial infrastructure holds the
potential for our product Kalios(TM) to help doctors and their patients
worldwide, while creating a strong partnership for Kalios(TM) and surgical
mitral valves using our technology. Affluent will continue to develop its
transcatheter mitral valve Epygon and its urinary incontinence artificial
sphincter Artus."

Kalios(TM) is the only mitral valve annuloplasty device that can be
percutaneously - and in a minimally invasive manner - adjusted by a
cardiologist (or surgeon) to treat residual and recurrent mitral
insufficiency at any time after implantation, repeatedly and on a beating
heart, thereby avoiding another open-heart surgery.

Affluent Medical's mitral valve technology mimics the anatomy and physiology
of a human valve, thereby potentially reducing the left ventricle workload
and improving the heart hemodynamics, restoring the natural blood flow
vortex in the left ventricle. It is expected to promote faster recovery of
patients with a seriously impaired cardiac condition.

About Affluent Medical

Affluent Medical is a French MedTech company, founded by Truffle Capital,
with the ambition to become a global leader in the treatment of structural
heart diseases, one of the world's leading cause of mortality, and urinary
incontinence, which currently affects one in four adults.

Affluent Medical develops next-generation, minimally invasive, innovative,
adjustable, and biomimetic implants to restore critical physiological
functions. The product candidates developed by the Company are all currently
in ongoing human clinical studies.

Subject to raising the necessary funds to finance its strategy and to
positive results from ongoing clinical studies, the Company's ambition is to
gradually commercialize its products in 2026, directly or indirectly.

For more information, visit www.affluentmedical.com

Contacts:

   AFFLUENT MEDICAL Sébastien LADET        SEITOSEI.ACTIFIN Financial communications / press
   Chief Executive Officer              relations Ghislaine GASPARETTO / Jennifer JULLIA +33
   (1)investor@affluentmedical.com                   (0)6 21 10 49 24 / +33 (0)1 56 88 11 19
   1.                                  (1)ghislaine.gasparetto@seitosei-actifin.com/(2)jenni
   mailto:investor@affluentmedical.                      fer.jullia@seitosei-actifin.com  1.
   com                                   mailto:ghislaine.gasparetto@seitosei-actifin.com 2.
                                                 mailto:jennifer.jullia@seitosei-actifin.com
   PRIMATICE Media relations France    MC SERVICES AG Media relations Europe Caroline
   Thomas ROBOREL de CLIMENS +33       BERGMANN / Kirsten RÜHL +49 (0)211 529252 20 / +49
   (0)6 78 12 97 95                    (0)211 529252 16 (1)affluent@mc-services.eu  1.
   (1)thomasdeclimens@primatice.com    mailto:affluent@mc-services.eu
   1.
   mailto:thomasdeclimens@primatice
   .com

---------------------------------------------------------------------------

12.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Affluent Medical SA
                   320 avenue Archimède - Les pléiades III Batiment B
                   13100 Aix-en-Provence
                   France
   E-mail:         affluent@mc-services.eu
   Internet:       www.affluentmedical.com
   ISIN:           FR0013333077
   EQS News ID:    1944723

End of News EQS News Service
---------------------------------------------------------------------------

1944723 12.07.2024 CET/CEST